WVE WAVE Life Sciences

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: .

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: . Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit and follow Wave on (formerly Twitter) and .

Investor Contact:

Kate Rausch



Media Contact:

Alicia Suter





EN
04/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Wave Life Sciences Ltd: 2 directors

Two Directors at Wave Life Sciences Ltd sold/sold after exercising options 227,351 shares at between 10.000USD and 10.098USD. The significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Wave Life Sciences Reports Second Quarter 2025 Financial Results and P...

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch